Novamind to Present at Benzinga Biotech Conference

Rhea-AI Summary

Novamind (CSE:NM)(OTC PINK:NVMDF) will participate in the Benzinga Biotech Small Cap Conference on March 25, 2021. The company’s CEO, Yaron Conforti, will present its vision for scaling access to psychedelic medicine at 9:25 AM EST. Conforti highlighted Novamind's growth since 2016 and the recent agreement to serve as a key clinical trial site for Merck. Additionally, Dr. Reid Robison, Novamind's Chief Medical Officer, will join a panel discussion on psychedelic therapies at 1:10 PM EST.

Panel discussion on psychedelic treatments and therapies to feature Novamind's Chief Medical Officer

TORONTO, ON / ACCESSWIRE / March 22, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the Benzinga Biotech Small Cap Conference ("the Conference"), a virtual conference taking place on March 25^th, 2021.

On Thursday, March 25^th, at 9:25am EST, Novamind's CEO and Director, Yaron Conforti, will present the Company's vision for scaling access to psychedelic medicine.

"Novamind's mental health clinics and contract research businesses have been operating with psychedelic medicine since 2016, and both businesses are currently experiencing significant growth," stated Yaron Conforti, CEO and Director of Novamind. "Our recently announced agreement to act as a key clinical trial site for Merck is one of many developments we're excited to share with investors."

The Conference will also host a panel discussion on the use of psychedelic therapies with industry leaders including Novamind's Chief Medical Officer, Dr. Reid Robison on Thursday, March 25^th at 1:10pm EST.

For more information about the conference, please click here.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information

Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512
Bill Mitoulas, Investor Relations
Email: bill@novamind.ca

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

View source version on accesswire.com:
https://www.accesswire.com/636697/Novamind-to-Present-at-Benzinga-Biotech-Conference

FAQ

When will Novamind present at the Benzinga Biotech Conference?

Novamind will present at the Benzinga Biotech Conference on March 25, 2021, at 9:25 AM EST.

Who is the CEO of Novamind?

The CEO of Novamind is Yaron Conforti.

What will Yaron Conforti discuss at the conference?

Yaron Conforti will discuss Novamind's vision for scaling access to psychedelic medicine.

Who will participate in the panel discussion on psychedelic therapies?

Dr. Reid Robison, Novamind's Chief Medical Officer, will participate in the panel discussion.

What is the significance of Novamind's agreement with Merck?

Novamind's agreement to act as a key clinical trial site for Merck signifies its growing role in psychedelic medicine research.